Ustekinumab in Crohn’s disease: evidence to date and place in therapy

Tal Engel, Uri Kopylov

Research output: Contribution to journalReview articlepeer-review


Crohn’s disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.

Original languageEnglish
Pages (from-to)208-214
Number of pages7
JournalTherapeutic Advances in Chronic Disease
Issue number4
StatePublished - 1 Jul 2016


  • Crohn’s disease
  • interleukin 12/23p40 inhibitor
  • ustekinumab


Dive into the research topics of 'Ustekinumab in Crohn’s disease: evidence to date and place in therapy'. Together they form a unique fingerprint.

Cite this